Joseph W. Ricigliano, Ph.D.

« Back to Attorneys Listing

Joseph W. Ricigliano, Ph.D.

Partner


Email
  Linkedin URL

2101 L Street NW
Suite 800
Washington, DC 20037
Tel: 202.448.1010
Fax: 973.331.1717


Expertise

  • Biotechnology
  • Chemical
  • Medical Devices
  • Pharmaceutical
  • Materials

Overview

Joe Ricigliano is a Partner in the firm’s Patent practice focusing on intellectual property, patent counseling, portfolio management, and strategy assessment. He has previously examined, prosecuted and counseled clients on a broad variety of technologies including life sciences (biochemical, immunological, pharmaceutical, agricultural, and medical device) applications and chemical/material science related applications. His experience includes prosecution and counseling related to complex immune protein constructs as therapeutics and protein conjugates for drug delivery. He also has substantial experience in high-tech coating technology, combinatorial chemistry (chemical diversity technologies including antibody and phage display), and diverse material science technologies including electroplating and nanomaterials (e.g., nanometals, nanocomposites and surface coating technologies). Joe has prepared and prosecuted both U.S. and foreign patent applications, working with scientists and in-house counsel to identify patentable subject matter and to secure its protection. He has advised pharmaceutical industry and clinical laboratory clients on compliance with the Clinical Laboratory Improvements Acts (CLIA). In addition, he has conducted investigations and advised clients on matters related to CLIA noncompliance issues and events. Joe has numerous years of laboratory experience prior to becoming an attorney. His research interests included viral mechanisms and pathogenesis and the development of steroidal based therapeutics including steroidal immunomodulators and evaluation of their mechanisms of action.


Bar & Court Admissions

  • District of Columbia
  • State of Virginia
  • Registered to practice before the U.S. Patent and Trademark Office

Education

  • American University Washington College of Law, J.D., cum laude, 2005
  • Waksman Institute of Microbiology, Postdoctoral Fellow
  • The University of Pennsylvania, Ph.D., Dept. of Biochemistry and Biophysics
  • Rutgers, The State University of New Jersey, B.A., Biochemistry, with highest distinction

Memberships

  • IPO U.S. Patent Law Committee Section, Current Member
  • American Bar Association, Nanotechnology Section, Former Member
  • Former Organizer/Coordinator for the American University/Washington College of Law’s International Patent Webinar Series

Successful Litigation

  • Carnegie Institution of Washington et al. v. Pure Grown Diamonds, Inc. et al., 1:20-cv-00189, S.D.N.Y. 2020
  • Carnegie Institution of Washington et al v. ALTR, Inc. et al., 1:20-cv-00198
  • U.S. Water Services, et al. v. Novozymes A/S, et al.
  • Modumetal Inc. v. Integran Technologies Inc.
  • Modumetal, Inc. v. Xtalic Corporation
  • Eppendorf AG, et al. v. Nanosphere Inc.
  • General Electric Company v. Martin R. Prince

Publications and Lectures

  • Neuronal reactivation of herpes simplex virus may involve interleukin-6. Kriesel J.D., Ricigliano, J.W., Spruance S.L., Garza H.H. and Hill J.M. Journal of Neurovirolgy 3(6): 441-448 (1997).
  • The salicylic acid signal for the activation of plant disease resistance: Induction, modification, perception, and transduction. Conrath U., Chen Z., Malamay J., Hennig J., Silvia H., Ricigliano J.W. and Klessig D.F. In “Modern Fungicides and Antifungal Compounds” Intercept Ltd. Andover, Hampshire, UK (1996).
  • Vitamin D3 as an adjutant with nucleic acid vaccine against herpes simplex type 2. Kriesel J.D., Ricigliano J.W., Zhu J., Sparuance S.L. and Araneo B.A. Abstract presented at 35th ICAAC, San Francisco, CA Sept. (1995).
  • Nucleic acid vaccine against herpes simplex virus type 2 (HSV-2): Use of a muscle specific promoter and the HSV-2 glycoprotein D (gD2) gene. Kriesel J.D., Zhu J., Ricigliano J.W., Sparuance S.L., Araneo B.A. Abstract presented at 35th ICAAC, San Francisco, CA Sept. (1995).
  • DNA vaccine protects mice from vaginitis and death due to herpes simplex type 2 (HSV-2). Kriesel J.D., Ricigliano J.W., Sparuance S.L., Araneo B.A. Abstract presented at the 8th international conference on antiviral research, Santa Fe, NM (1995).
  • Two inducers of plant defense responses, 2,6-dichloroisonicotinic acid and salicylic acid, inhibit catalase activity in tobacco. Conrath U., Chen Z., Ricigliano J.W., Kessmann H. and Klessig D.F. Proc. Natl. Acad. Sci. U.S.A. 92: 7143-7147 (1995).
  • High Molecular weight complexes of the adenovirus DNA-binding protein. Ricigliano J.W., Brough D.E. and Klessig D.F. Virology 202: 715-723 (1994).
  • Purification and Characterization of a soluble salicylic acid binding-protein from tobacco. Chen Z., Ricigliano J.W., and Klessig D.F. Proc. Natl. Acad. Sci. U.S.A. 90: 9533-9537 (1993).
  • Studies on the multifunctional adenovirus DNA binding protein. Brough D.E., Ricigliano J.W. and Klessig D.F. In “Molecular biology of SV40, polyoma and adenoviruses.” Cold Spring Harbor Press. Abstract presented at the DNA Tumor Virus conference, Cold Spring Harbor, NY (1992).
  • Mechanism based inactivators of hydroxysteroid dehydrogenases. (invited review) Ricigliano J.W. and Penning T.M., Journal of Enzyme Inhibition 165-198 (1991).
  • The kinetic mechanism of 3 α-hydroxysteroid dehydrogenase. Askonas L.J., Ricigliano J.W. and Penning T.M. Biochemical J. 269: 749-755 (1991).
  • Clues to the development of mechanism based inactivators of 3 α-hydroxysteroid dehydrogenase: Comparison of steroidal and nonsteroidal Michael acceptors and epoxides. Penning T.M., Thornton R., and Ricigliano J.W. Steroids 56: 420-427 (1991).
  • A direct in vitro effect of 5 α-dihydrotestosterone on testosterone production by isolated leydig precursor cells. Hardy M. P., Zhou Z., Penning T.M., Ricigliano J.W., Nonneman D., Ganjam V. K., and Ewing L.L., XIth North American Testis Workshop. Annals of the N.Y. Academy of Sciences 637: 152-163 (1991).
  • Evidence that enzyme-generated aromatic Michael acceptors covalently modify the nucleotide binding site of 3 α-hydroxysteroid dehydrogenase. Ricigliano J.W. and Penning T.M. Biochemical J. 269: 749-755 (1990).
  • Synthesis and evaluation of mechanism based inactivators of 3 α-hydroxysteroid dehydrogenase. Ricigliano J.W. and Penning T.M. Biochemical J. 269: 139-149 (1989).
  • Covalent modification of he NAD(P)+ Binding site of 3 α-hydroxysteroid dehydrogenase by a nonsteroidal mechanism-based inactivator. Ricigliano J.W. and Penning T.M. Federation Proceedings 47, Abstract #4067 (1988).
  • Analysis of the ATPase mechanism of myosin sub-fragment 1 from insect fibrillar flight muscle in the presence and absence of actin, using phosphate-water oxygen exchange measurements. White D.S.C., Ricigliano J.W., and Webb M.R. J. Muscle Research and Cell Motility 8:537-540 (1987).
  • Inactivation of 3 α-hydroxysteroid dehydrogenase by a nonsteroidal suicide substrate. Ricigliano J.W. and Penning T.M. Federation Proceedings 46: 2273, Abst # 2026 (1987).
  • Active-Site directed inactivation of 20 α-hydroxysteroid dehydrogenase. Ricigliano J.W. and Penning T.M. Federation Proceedings 45: 326 Abstract #1001 (1986).
  • Active-Site directed inactivation of 20 α-hydroxysteroid dehydrogenase. Ricigliano J.W. and Penning T.M. Biochemical J. 240: 717-723 (1986).
  • “Preparation and properties of copper depleted cytochrome c oxidase.” Thesis in partial fulfillment of the requirements of the degree: Bachelor of the Arts. Rutgers University, New Brunswick, NJ (1982).